Latest news with #MAIA
Business Wire
4 days ago
- Business
- Business Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST). 'Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC. 'By the end of this year, we expect to have all required approvals to begin enrolling patients in a HCC trial,' Dr. Vitoc added. MAIA was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for ateganosine as a treatment for HCC in 2022. ODDs can provide up to seven years of market exclusivity. Dr. David Pinato is a clinician scientist in the Department of Surgery and Cancer at Imperial College London and a consultant oncologist at Imperial College Healthcare NHS Trust. As Director of Developmental Cancer Therapeutics at Imperial College, he leads a translational research program focused on the early clinical implementation of novel experimental anticancer therapies with particular emphasis on anti-cancer immunotherapy. Dr. Pinato's research efforts in liver cancer have been recognized by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). He has received awards by the British Society of Pharmacology and the Royal Society of Medicine, and fellowships by the European School of Oncology and Fulbright Program. Dr. Pinato completed his core medical training across some of the busiest acute hospitals in London and was elected to the Royal College of Physicians (MRCP). His research has been published in leading journals in the field including the Journal of Clinical Oncology, Annals of Oncology, Hepatology and many others. Dr. Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for several peer-reviewed journals including The Lancet, Cancer Discovery, Hepatology and Journal of Hepatology. Dr. Claudia Fulgenzi is a specialist in medical oncology at Imperial College London, with dedicated professional interest in the field of immune-oncology and gastro-intestinal cancers, particularly hepatic-biliary malignancies. Dr. Fulgenzi graduated in medicine from the University of Rome Tor Vergata and subsequently specialized in medical oncology at the University Campus Bio Medico of Rome, Italy. Her contributions to the field have been recognized with prestigious awards including the ASCO Merit Award, the Young Investigator award by the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology. Dr. Fulgenzi is actively engaged in clinical practice in London, serving as an honorary consultant in oncology at Chelsea and Westminster Hospital and as a specialty doctor in the early phase clinical trial unit at Hammersmith Hospital. In these capacities, she conducts clinical and translational research, contributes to clinical trial design, and provides expert medical guidance to cancer patients. Hepatocellular carcinoma is the most frequently occurring primary liver tumor representing approximately 90% of all liver cancers. HCC currently ranks 5th by incidence and 3rd by mortality on a global scale. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
Hindustan Times
4 days ago
- Business
- Hindustan Times
MAIA Estates plans ₹3,000 crore investment to scale up its real estate presence in Bengaluru
Bengaluru-based real estate developer MAIA Estates plans to launch over 4 million sq ft of new housing and commercial projects this financial year, backed by an investment of ₹ 3,000 crore, founder and CEO of the company, Mayank Ruia told Bengaluru-based real estate developer MAIA Estates plans to launch over 4 million sq ft of new housing and commercial projects this financial year, backed by an investment of ₹ 3,000 crore, founder and CEO of the company, Mayank Ruia told . With this expansion, the company's total development footprint in Bengaluru is expected to exceed 2.5 million sq ft by year-end. "The upcoming projects will span across a wide price range, starting from ₹ 2 crore and going up to ₹ 12 crore, with high-end residences priced above ₹ 15,000 per sq ft," Ruia said. Housing projects pipeline Among the developer's recent highlights is the completion of its flagship residential asset, 27 Summit, delivered in 3.5 years. Positioned in the super-luxury segment, homes in the project are priced between ₹ 21 crore and ₹ 27 crore, with rates starting at ₹ 47,000 per sq. ft. Currently, MAIA has 6 to 8 residential projects at various stages, from planning to sales and construction. The company expects to launch 1.5–2 million sq. ft. of new space in FY2026, targeting a cumulative footprint of 2–2.5 million sq. ft. in Bengaluru alone by year-end. "Ticket sizes for its homes range between ₹ 2 crore and ₹ 12 crore, with select properties priced upwards of ₹ 12,000 per sq ft," Ruia said. Nearly 50–60% of MAIA's residential inventory lies in North Bengaluru, where prices vary from ₹ 2.5 crore to ₹ 12 crore. MAIA's developments are concentrated within Bengaluru's inner ring and fast-developing zones in the north. "While prime city-centre areas like Richmond Road and Basavanagudi are earmarked for ultra-luxury residential projects, eastern Bengaluru remains a cautious choice for the brand," he said. Beyond Bengaluru, MAIA made its debut in Chennai in late 2024 with an ultra-luxury residential project comprising eight exclusive homes priced around ₹ 20 crore each. The project is nearly sold out, and additional launches are planned in the city. "The company's development plans are projected to require around ₹ 3,000 crore in capital. Funding will be structured with a one-third split across equity, construction finance, and customer sales," Ruia said. Also Read: Bengaluru's priciest real estate deal: Luxury penthouse in Central Business District sells for more than ₹ 54 crore Foray into commercial real estate MAIA has already raised over ₹ 1,000 crore from CapitaLand for its commercial venture and secured over ₹ 300 crores in the past for residential development through internal accruals and partners It entered the commercial real estate market in February 2025 through a marquee transaction with global real estate player CapitaLand. 'The move complements MAIA's traditionally residential-centric portfolio and is expected to significantly boost its long-term asset base. Plans are underway to triple the company's office footprint over the next 3–4 years, with key focus areas including Bengaluru's Central Business District (CBD), Hebbal, and the Outer Ring Road (ORR),' he said. MAIA currently has 1.5 million sq. ft. of commercial space under development, with future growth pegged to the availability of high-potential land parcels. All ongoing office projects are standalone, and future developments are expected to follow an opportunity-led strategy.
The Wire
5 days ago
- Automotive
- The Wire
PPS Motors - Mahindra's Largest Dealer in India - Expands its Operations in Maharashtra; Inaugurates 2 New Dealerships at Katraj, Pune and Saswad
Pune, Maharashtra, India (NewsVoir) • Marks Group's 137th Mahindra facility in India; a new touchpoint at Katraj apart from another at Saswad launched • The 6,500 sq. ft. Katraj showroom strengthens PPS Motors' presence to 8 Mahindra outlets in Pune • PPS Motors plans to add 5 more facilities in the city to further enhance accessibility and customer experience PPS Motors, a part of one of India's largest automobile retail conglomerates, today announced the inauguration of two newest Mahindra dealerships in Pune, Maharashtra. The inauguration of the facility at Katraj, Ambegaon was attended by Mr. Baneswar Banerjee, National Sales Head & VP, Mahindra, and other senior officials from both the organizations. Apart from this, the company had also inaugurated another dealership at Saswad near Pune. The latest facility, strategically located at Katraj, Ambegaon along the bustling NH-4 corridor, sits at the heart of one of Pune's key automotive hubs. This 6,500 sq. ft. showroom can display 6 vehicles together and is designed to provide holistic customer experience - offering Mahindra's full range of Passenger Vehicles (ICE & EV). With a modern colour palette, dramatic lighting, intuitive technology and a seamless interaction, every element of the space in the dealership showroom is crafted to evoke the sense of progressive design, intelligent innovation and refined elegance. The customers will step into an immersive environment complete with a showcase of Mahindra's breakthrough technologies - from the INGLO Electric Origin architecture to MAIA, the fastest automotive mind in the world along with Hero features. With this launch, PPS Motors further strengthens its extensive footprint in India as the group now operates 137 Mahindra touchpoints in six states – Maharashtra, Andhra Pradesh, Telangana, Kerala Karnataka, and Tamil Nadu. In FY 2025 alone, the group sold over 37,000 Mahindra vehicles, underscoring its position as Mahindra's largest sales and after-sales partner in India. PPS Motors – Scaling Ambitions in Pune The Katraj dealership marks PPS Motors' 8th Mahindra touchpoint in Pune, comprising 7 showrooms and 1 workshop. Having entered the Pune market in July 2024, the group has already sold over 2,500 Mahindra vehicles in the city in under a year's time. With a robust expansion plan in place, PPS Motors aims to add 3 more showrooms and 2 workshops, taking the total to 13 Mahindra touchpoints in Pune region. With this enhanced presence, the company is targeting to double its annual sales from Pune to 4,500 to 5,000 vehicles, with an estimated revenue of Rs.800 - 1,000 crore in the next one year. Commenting on the inauguration, Mr. Rajiv Sanghvi, Managing Director, PPS Motors, said, 'We are excited to strengthen our longstanding partnership with Mahindra with the inauguration of our 137th Mahindra facility. Our journey with Mahindra spans nearly seven decades and is built on a foundation of shared values, trust, and customer-first thinking. With our deep understanding of evolving customer needs and Mahindra's advanced, future-ready vehicles, we remain committed to delivering a truly best-in-class ownership experience.' In 2024, as per industry reports, Maharashtra witnessed a 3.93 per cent increase with around 4,50,000 cars as compared to 4,33,000 cars in 2023. The state of Maharashtra was also the top buyer of electric cars and SUVs in the period between January to April 2025, data on Vahan portal revealed. About PPS Motors PPS Motors is part of a larger automobile group - one of the country's largest spread automobile conglomerates - with rich experience of 75 years, operates through 720 automobile touchpoints across 18 states supported by a dedicated team of over 18,000 expert professionals. PPS Motors provides exceptional service and upholds high standards of professionalism. PPS Motors represents a diverse spectrum of auto segments, including 18 brands in passenger vehicles, light and heavy commercial vehicles, and construction equipment. The conglomerate stands as a formidable force representing 20 renowned brands and registered an annual group turnover of INR 18,800 crores in FY 2024. (Disclaimer: The above press release comes to you under an arrangement with Newsvoir and PTI takes no editorial responsibility for the same.).
Fashion Value Chain
5 days ago
- Automotive
- Fashion Value Chain
PPS Motors – Mahindra's Largest Dealer in India – Expands its Operations in Maharashtra; Inaugurates 2 New Dealerships at Katraj, Pune and Saswad
Marks Group's 137th Mahindra facility in India; a new touchpoint at Katraj apart from another at Saswad launched The 6,500 sq. ft. Katraj showroom strengthens PPS Motors' presence to 8 Mahindra outlets in Pune PPS Motors plans to add 5 more facilities in the city to further enhance accessibility and customer experience PPS Motors, a part of one of India's largest automobile retail conglomerates, today announced the inauguration of two newest Mahindra dealerships in Pune, Maharashtra. The inauguration of the facility at Katraj, Ambegaon was attended by Mr. Baneswar Banerjee, National Sales Head & VP, Mahindra, and other senior officials from both the organizations. Apart from this, the company had also inaugurated another dealership at Saswad near Pune. Baneswar Banerjee, National Sales Head & VP, Mahindra, senior officials from PPS Motors and Mahindra inaugurating PPS Mahindra Showroom at Katraj, Pune on Monday June 23, 2025 The latest facility, strategically located at Katraj, Ambegaon along the bustling NH-4 corridor, sits at the heart of one of Pune's key automotive hubs. This 6,500 sq. ft. showroom can display 6 vehicles together and is designed to provide holistic customer experience – offering Mahindra's full range of Passenger Vehicles (ICE & EV). With a modern colour palette, dramatic lighting, intuitive technology and a seamless interaction, every element of the space in the dealership showroom is crafted to evoke the sense of progressive design, intelligent innovation and refined elegance. The customers will step into an immersive environment complete with a showcase of Mahindra's breakthrough technologies – from the INGLO Electric Origin architecture to MAIA, the fastest automotive mind in the world along with Hero features. With this launch, PPS Motors further strengthens its extensive footprint in India as the group now operates 137 Mahindra touchpoints in six states – Maharashtra, Andhra Pradesh, Telangana, Kerala Karnataka, and Tamil Nadu. In FY 2025 alone, the group sold over 37,000 Mahindra vehicles, underscoring its position as Mahindra's largest sales and after-sales partner in India. PPS Motors – Scaling Ambitions in Pune The Katraj dealership marks PPS Motors' 8th Mahindra touchpoint in Pune, comprising 7 showrooms and 1 workshop. Having entered the Pune market in July 2024, the group has already sold over 2,500 Mahindra vehicles in the city in under a year's time. With a robust expansion plan in place, PPS Motors aims to add 3 more showrooms and 2 workshops, taking the total to 13 Mahindra touchpoints in Pune region. With this enhanced presence, the company is targeting to double its annual sales from Pune to 4,500 to 5,000 vehicles, with an estimated revenue of Rs.800 – 1,000 crore in the next one year. Commenting on the inauguration, Mr. Rajiv Sanghvi, Managing Director, PPS Motors, said, 'We are excited to strengthen our longstanding partnership with Mahindra with the inauguration of our 137th Mahindra facility. Our journey with Mahindra spans nearly seven decades and is built on a foundation of shared values, trust, and customer-first thinking. With our deep understanding of evolving customer needs and Mahindra's advanced, future-ready vehicles, we remain committed to delivering a truly best-in-class ownership experience.' In 2024, as per industry reports, Maharashtra witnessed a 3.93 per cent increase with around 4,50,000 cars as compared to 4,33,000 cars in 2023. The state of Maharashtra was also the top buyer of electric cars and SUVs in the period between January to April 2025, data on Vahan portal revealed. About PPS Motors PPS Motors is part of a larger automobile group – one of the countrys largest spread automobile conglomerates – with rich experience of 75+ years, operates through 720+ automobile touchpoints across 18 states supported by a dedicated team of over 18,000 expert professionals. PPS Motors provides exceptional service and upholds high standards of professionalism. PPS Motors represents a diverse spectrum of auto segments, including 18 brands in passenger vehicles, light and heavy commercial vehicles, and construction equipment. The conglomerate stands as a formidable force representing 20 renowned brands and registered an annual group turnover of INR 18,800 crores in FY 2024.
Business Wire
18-06-2025
- Business
- Business Wire
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA's telomere-targeting agent ateganosine (THIO), sequenced with Roche's checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers. 'In preclinical studies, ateganosine was found to be highly synergistic and effective in combination with Roche's anti-PD-L1 agent atezolizumab,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'We are pleased to partner with world-renowned Roche and we look forward to further strengthening our mission to find safe and effective cancer treatments.' About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activate both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. Forward-Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
